Document is current
Any future updates will be listed below
-
Authors
Alexanian, Michael
Przytycki, Pawel F. https://orcid.org/0000-0002-3360-6936
Micheletti, Rudi
Padmanabhan, Arun
Ye, Lin
Travers, Joshua G. https://orcid.org/0000-0002-5660-2620
Gonzalez-Teran, Barbara https://orcid.org/0000-0002-4336-8644
Silva, Ana Catarina
Duan, Qiming https://orcid.org/0000-0002-6204-3028
Ranade, Sanjeev S.
Felix, Franco https://orcid.org/0000-0002-4297-7149
Linares-Saldana, Ricardo https://orcid.org/0000-0003-2657-825X
Li, Li
Lee, Clara Youngna https://orcid.org/0000-0002-9402-4155
Sadagopan, Nandhini
Pelonero, Angelo https://orcid.org/0000-0002-7684-3771
Huang, Yu
Andreoletti, Gaia
Jain, Rajan
McKinsey, Timothy A.
Rosenfeld, Michael G.
Gifford, Casey A.
Pollard, Katherine S. https://orcid.org/0000-0002-9870-6196
Haldar, Saptarsi M. https://orcid.org/0000-0001-7968-9696
Srivastava, Deepak https://orcid.org/0000-0002-3480-5953
- License Information
-
More Information
Article History
Received: 17 July 2020
Accepted: 26 May 2021
First Online: 23 June 2021
Competing interests
: D.S. is a scientific co-founder, shareholder and director of Tenaya Therapeutics. S.M.H. is an executive, officer and shareholder of Amgen, a scientific co-founder and shareholder of Tenaya Therapeutics, and serves on the scientific advisory board of DZHK (German Centre for Cardiovascular Research). K.S.P. is a shareholder of Tenaya Therapeutics. T.A.M. is on the scientific advisory board of Artemes Bio, Inc., received funding from Italfarmaco for an unrelated project, and has a subcontract from Eikonizo Therapeutics related to an SBIR grant from the National Institutes of Health (HL154959).
